Investment
Features
FeesSafety
Academy
More
Pluang+

Hims & Hers shares jump 40% post-Novo deal, outlook boosted by GLP-1 and international growth potential.

Analyst Insights
27 Mar 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Hims & Hers Health shares surged to about $27 following a deal with Novo, then settled around $20, marking a 40% gain from previous levels. Despite high short interest at 40% of the float, reduced short selling pressure suggests growing investor confidence. The company projects FY2025 revenue of $2.35 billion and anticipates up to $2.9 billion in FY2026, driven by rising ARPU and potential catalysts from GLP-1 products and international expansion. While valuation reflects execution risks, the outlook indicates significant upside if growth initiatives succeed.

More News (HIMS)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App